Default company panoramic image

Phoenix Nuclear Labs

PNL has developed a proprietary high flux neutron generator for defense, medical, and commercial aerospace applications.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Madison, WI, USA
  • Currency USD
  • Founded July 2005
  • Employees 20
  • Website

Company Summary

Phoenix Nuclear Labs (PNL) is an early stage ($2M revenue) technology design and manufacturing company that has developed a proprietary neutron generator technology and is well positioned to enter the defense, aerospace, and medical markets within the next three years. PNL has a committed $9.5M in DoD and DoE grant funding for 2014/2015. Projected revenue in 2016-2018 from 2 early customers (US Army and SHINE Medical Technologies) is $50M.


  • Default avatar
    Ross Radel

    Dr. Ross Radel has been President of PNL since 2011. Prior to joining PNL, he was a Senior Member of the Technical Staff at Sandia National Labs. He has a PhD in Nuclear Engineering from UW-Madison. PNL has tripled in size during Ross’s tenure.

  • Default avatar
    Evan Sengbusch
    VP of Business Development

    Dr. Evan Sengbusch is UW-Madison’s first joint PhD/MBA (Medical Physics/Technology Management) and has consulting experience with several early stage technology and venture investment companies. Since joining PNL in 2012, he has brought in over $6M in committed funding and has drastically expanded PNL’s market reach.

  • Default avatar
    Tye Gribb
    VP of Research and Development

    Dr. Tye Gribb has over 20 years of experience leading early stage technology companies. He was the co-founder of Imago Scientific Instruments (now part of Cameca Instruments) where he led the development of the Local Electrode Atom Probe (LEAP), Imago’s flagship product, from initial sketches through commercialization where it has generated over $120M in revenue.

  • Default avatar
    Steve Books
    VP of Operations

    Mr. Books has extensive experience in Operations at entrepreneurial manufacturing organizations. As part of Marquette Medical Systems, Steve was responsible for the P&L of the $200 million Cardiology. GE purchased MMS in 1999 and Steve began managing Global Operations and Supply Chain for GE-Marquette. Steve was later responsible for R&D, Service, Manufacturing and H/R as COO of TomoTherapy.


  • Default avatar
    Paul Wrycha
    Default avatar

Previous Investors

  • Default avatar
    Wisconsin Investment Partners
    Default avatar
    Knox LLC
    Default avatar
    Venture Management LLC